BridgeBio Pharma (BBIO) Stock Overview
A biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
BBIO Community Fair Values
Create NarrativeSee what 36 others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
BridgeBio Pharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$71.39 |
| 52 Week High | US$84.94 |
| 52 Week Low | US$28.33 |
| Beta | 1.18 |
| 1 Month Change | -1.24% |
| 3 Month Change | -3.61% |
| 1 Year Change | 119.05% |
| 3 Year Change | 400.98% |
| 5 Year Change | 4.04% |
| Change since IPO | 159.13% |
Recent News & Updates
Recent updates
BridgeBio Pharma (BBIO) From Biotech Blueprint to Commercial Powerhouse
BridgeBio Pharma (BBIO) has successfully transitioned into a commercial-stage juggernaut, with shares trading at $68.14 as of February 22, 2026. The company is currently riding the momentum of its primary growth engine, Attruby (acoramidis) , which reported preliminary 2025 revenues of $362.4 million.BridgeBio: Initiating At A Neutral Rating, Stock Priced At Perfection
Feb 09
Precision Medicine And Pipeline Advancements Will Expand Biotech Horizons
Strong growth in a key drug and diversified late-stage pipeline position BridgeBio for sustained revenue momentum, market leadership, and improved profit margins.BridgeBio Pharma, Inc. (NASDAQ:BBIO) Just Released Its Second-Quarter Earnings: Here's What Analysts Think
Aug 09
Pinning Down BridgeBio Pharma, Inc.'s (NASDAQ:BBIO) P/S Is Difficult Right Now
Apr 28BridgeBio: Early Signs Point To Blockbuster Revenues
Apr 22BridgeBio: Post Attruby Approval, Shares Don't Look Such Good Value - Rating Downgrade
Feb 07BridgeBio Pharma Is A Buy On Dips After Attruby's FDA Approval
Jan 15BridgeBio: Next Chapter Begins After Attruby Approval
Nov 24BridgeBio: With HELIOS-B Overhang Removed, Focus To Turn To Approval And Launch Of Acoramidis
Aug 31Shareholder Returns
| BBIO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 7.3% | -0.5% | -1.5% |
| 1Y | 119.1% | 27.4% | 21.2% |
Return vs Industry: BBIO exceeded the US Biotechs industry which returned 28.2% over the past year.
Return vs Market: BBIO exceeded the US Market which returned 21.7% over the past year.
Price Volatility
| BBIO volatility | |
|---|---|
| BBIO Average Weekly Movement | 7.9% |
| Biotechs Industry Average Movement | 10.5% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: BBIO has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: BBIO's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 837 | Neil Kumar | bridgebio.com |
BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NULIBRY brand name; and low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 clinical stage or the treatment of children with achondroplasia and hypochondroplasia. It also develops Encaleret, an oral small molecule, negative allosteric modulator of the calcium sensing receptor, which is in phase 3 clinical study for the treatment of Autosomal Dominant Hypocalcemia Type 1(ADH1) and Chronic Hypoparathyroidism (CHP); BBP-418, an investigational, orally administered, and small molecule therapy that is in phase 3 clinical study for the treatment of LGMD2I; and BBP-812, an investigational adeno-associated virus (AAV) gene therapy for Canavan disease.
BridgeBio Pharma, Inc. Fundamentals Summary
| BBIO fundamental statistics | |
|---|---|
| Market cap | US$14.41b |
| Earnings (TTM) | -US$724.93m |
| Revenue (TTM) | US$502.08m |
Is BBIO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BBIO income statement (TTM) | |
|---|---|
| Revenue | US$502.08m |
| Cost of Revenue | US$20.96m |
| Gross Profit | US$481.11m |
| Other Expenses | US$1.21b |
| Earnings | -US$724.93m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.74 |
| Gross Margin | 95.82% |
| Net Profit Margin | -144.39% |
| Debt/Equity Ratio | -89.2% |
How did BBIO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/11 12:12 |
| End of Day Share Price | 2026/03/11 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
BridgeBio Pharma, Inc. is covered by 35 analysts. 20 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Eliana Merle | Barclays |
| William Pickering | Bernstein |
| Jason Zemansky | BofA Global Research |